Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Emesis (Vomiting) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Emesis (Vomiting) - Pipeline Review, H1 2015', provides an overview of the Emesis (Vomiting)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Emesis (Vomiting), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emesis (Vomiting) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Emesis (Vomiting) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Emesis (Vomiting) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Emesis (Vomiting) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Emesis (Vomiting) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Emesis (Vomiting) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Emesis (Vomiting) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Emesis (Vomiting) Overview 6 Therapeutics Development 7 Pipeline Products for Emesis (Vomiting) - Overview 7 Pipeline Products for Emesis (Vomiting) - Comparative Analysis 8 Emesis (Vomiting) - Therapeutics under Development by Companies 9 Emesis (Vomiting) - Therapeutics under Investigation by Universities/Institutes 10 Emesis (Vomiting) - Pipeline Products Glance 11 Early Stage Products 11 Emesis (Vomiting) - Products under Development by Companies 12 Emesis (Vomiting) - Products under Investigation by Universities/Institutes 13 Emesis (Vomiting) - Companies Involved in Therapeutics Development 14 Astellas Pharma Inc. 14 Daewoong Pharmaceutical Co., Ltd. 15 Epiomed Therapeutics, Inc. 16 Emesis (Vomiting) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Molecule Type 22 Drug Profiles 24 Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 DWJ-1308 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ETI-0001 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ETI-385 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 FK-886 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Emesis (Vomiting) - Dormant Projects 30 Emesis (Vomiting) - Discontinued Products 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 33 Disclaimer 34
List of Tables Number of Products under Development for Emesis (Vomiting), H1 2015 7 Number of Products under Development for Emesis (Vomiting) - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Emesis (Vomiting) - Pipeline by Astellas Pharma Inc., H1 2015 14 Emesis (Vomiting) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 15 Emesis (Vomiting) - Pipeline by Epiomed Therapeutics, Inc., H1 2015 16 Assessment by Monotherapy Products, H1 2015 17 Number of Products by Stage and Target, H1 2015 19 Number of Products by Stage and Mechanism of Action, H1 2015 21 Number of Products by Stage and Molecule Type, H1 2015 23 Emesis (Vomiting) - Dormant Projects, H1 2015 30 Emesis (Vomiting) - Dormant Projects (Contd..1), H1 2015 31 Emesis (Vomiting) - Discontinued Products, H1 2015 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.